NKTR

Nektar Therapeutics

64.39

Jul 01 • 04:00PM ET -5.42 (-7.76%)

Healthcare Biotechnology USA Mid NASD

Jun 30, 1:01 PMABVX positive Phase 3 UC data sparks retail sympathy surge in NKTR

Peers: INCY VKTX BMRN RYTM AXSM KROS KRYS MDGL NBIX BIIB

| Held by: VTI IWM VXF IWO SCHA XPH VHT IHE PRFZ LFSC

Scroll to Statements

Index	RUT
Market Cap	2.18B
Enterprise Value	1.75B
Income	-158.10M
Sales	55.63M
Book/sh	28.28
Cash/sh	16.83
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	63
IPO	May 03, 1994

P/E	-
Forward P/E	-
PEG	-
P/S	39.11
P/B	2.28
P/C	3.83
P/FCF	-
EV/EBITDA	-
EV/Sales	31.46
Quick Ratio	10.21
Current Ratio	10.21
Debt/Eq	0.25
LT Debt/Eq	0.21
Option/Short	Yes / Yes

EPS (ttm)	-8.42
EPS next Y	-11.07
EPS next Q	-2.04
EPS this Y	6.87%
EPS next Y	-22.20%
EPS next 5Y	-5.42%
EPS past 3/5Y	30.93% 23.59%
Sales past 3/5Y	-15.66% -18.43%
EPS Y/Y TTM	11.52%
Sales Y/Y TTM	-36.24%
EPS Q/Q	49.83%
Sales Q/Q	3.83%
Earnings	May 07 AMC
EPS/Sales Surpr.	-15.02% 1.59%

Insider Own	3.40%
Insider Trans	-2.60%
Inst Own	76.70%
Inst Trans	27.12%
ROA	-31.01%
ROE	-53.60%
ROIC	-22.68%
Gross Margin	98.65%
Oper. Margin	-224.08%
Profit Margin	-284.18%
SMA20	4.71%
SMA50	-9.38%
SMA200	4.46%
Trades

Shs Outstand	33.79M
Shs Float	32.64M
Short Float	15.15%
Short Ratio	4.40
Short Interest	4.94M
52W High	109.00 -40.93%
52W Low	21.02 206.33%
Volatility	6.88% 5.69%
ATR (14)	3.77
RSI (14)	49.08
Beta	-0.83
Rel Volume	1.41
Avg Volume	1.12M
Volume	1,590,849

Perf Week	-0.69%
Perf Month	0.83%
Perf Quarter	-10.51%
Perf Half Y	50.69%
Perf YTD	52.29%
Perf Year	161.85%
Perf 3Y	646.29%
Perf 5Y	-75.50%
Perf 10Y	-70.19%
Recom	1.20
Target Price	153.25
Prev Close	69.81
Price	64.39
Change	-7.76%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-24-26	Initiated	Wedbush	Neutral	$70
Mar-17-26	Initiated	TD Cowen	Buy
Feb-10-26	Upgrade	William Blair	Mkt Perform → Outperform
Nov-26-25	Initiated	Citigroup	Buy	$102
Jun-24-25	Reiterated	H.C. Wainwright	Buy	$6.50 → $120
Jun-24-25	Reiterated	BTIG Research	Buy	$60 → $100
Apr-11-25	Upgrade	Jefferies	Hold → Buy	$2
Mar-14-25	Upgrade	Oppenheimer	Perform → Outperform	$6
Jan-08-25	Initiated	B. Riley Securities	Buy	$4
Dec-10-24	Initiated	H.C. Wainwright	Buy	$6.50
Nov-04-24	Initiated	Piper Sandler	Overweight	$7
Sep-30-24	Resumed	BTIG Research	Buy	$4
Jun-28-24	Initiated	Rodman & Renshaw	Buy	$2
Nov-20-23	Resumed	JP Morgan	Underweight
Nov-09-23	Upgrade	TD Cowen	Market Perform → Outperform
May-10-23	Upgrade	Jefferies	Underperform → Hold	$1.50 → $1
Feb-24-23	Downgrade	Jefferies	Hold → Underperform	$3.20 → $1.50
Aug-08-22	Downgrade	JP Morgan	Neutral → Underweight
May-31-22	Resumed	Jefferies	Hold	$12 → $4
Apr-18-22	Downgrade	Goldman	Neutral → Sell	$3

Show Previous Ratings

Jun-26-26 04:30PM	Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jun-03-26 04:15PM	Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
May-27-26 06:15PM	Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York (PR Newswire)
May-08-26 08:30AM	Nektar Therapeutics Q1 2026 Earnings Call Summary (Moby)
May-07-26 05:18PM	Nektar: Q1 Earnings Snapshot (Associated Press)
04:15PM	Loading…
04:15PM	Nektar Therapeutics Reports First Quarter 2026 Financial Results (PR Newswire)
May-01-26 04:39PM	Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Apr-28-26 06:00PM	Nektar to Announce Financial Results for the First Quarter on Thursday, May 7, 2026, After Close of U.S.-Based Financial Markets (PR Newswire)
Apr-23-26 04:15PM	Nektar Therapeutics Announces Closing of $373.8 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)
Apr-21-26 09:30PM	Nektar Therapeutics Announces Pricing of Upsized $325 Million Public Offering (PR Newswire) -5.05%
Apr-20-26 04:01PM	Nektar Therapeutics Announces Proposed Public Offering (PR Newswire) +18.25%
02:34PM	Market Feels Weak, But Stocks Tell Stories (GuruFocus.com)
12:43PM	Nektar Therapeutics Adds To Its 129% Two-Month Run With Alopecia News (Investor's Business Daily)
11:43AM	This Biotech Stock Soars on Hair Loss Trial Results. It's Not a Cure for Baldness. (Barrons.com)
08:01AM	Nektar surges again as alopecia drug shows new promise in extension study (BioPharma Dive)
07:30AM	Loading…
07:30AM	52-Week Topline Results from 16-Week Blinded Treatment Extension of REZOLVE-AA Demonstrate Deepening of Responses in Severe-to-Very-Severe Alopecia Areata with Rezpegaldesleukin (PR Newswire)
Apr-19-26 12:00PM	Nektar to Hold Conference Call to Discuss 52-Week Topline Results from the 16-Week Extension Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on April 20, 2026 (PR Newswire)
Mar-28-26 12:36PM	Data from Phase 2b REZOLVE-AD and REZOLVE-AA Studies of Rezpegaldesleukin Presented at 2026 American Academy of Dermatology Annual Meeting (PR Newswire)
Mar-27-26 10:34AM	Short Squeeze Stocks: The Usual Suspects, & One Newcomer (Schaeffer's Research)
Mar-23-26 08:15AM	Apogee strengthens case for longer-lasting eczema drug (BioPharma Dive)
Mar-20-26 10:00AM	Data from Phase 2b Studies for Rezpegaldesleukin Accepted for Two Oral Presentations at the 2026 American Academy of Dermatology Annual Meeting (PR Newswire)
Mar-17-26 09:33AM	DraftKings, Eli Lilly downgraded: Wall Street's top analyst calls (The Fly)
Mar-16-26 03:09AM	Nektar Therapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - NKTR (PR Newswire)
Mar-13-26 08:30AM	Nektar Therapeutics Q4 2025 Earnings Call Summary (Moby)
Mar-12-26 11:05PM	Nektar Therapeutics (NKTR) Q4 2025 Earnings Call Highlights: Promising Phase 2B Results and ... (GuruFocus.com)
04:41PM	Nektar: Q4 Earnings Snapshot (Associated Press Finance)
04:15PM	Nektar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results (PR Newswire)
Mar-10-26 08:30AM	Nektar Therapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights NKTR (Business Wire)
07:10AM	Esperion Therapeutics (ESPR) Misses Q4 Earnings Estimates (Zacks)
Mar-06-26 06:00PM	Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
10:00AM	Loading…
Mar-05-26 10:00AM	Analysts Estimate Nektar Therapeutics (NKTR) to Report a Decline in Earnings: What to Look Out for (Zacks)
Feb-26-26 06:00PM	Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial Markets (PR Newswire) -6.35%
Feb-25-26 09:55AM	Wall Street Analysts Think Nektar (NKTR) Could Surge 89.8%: Read This Before Placing a Bet (Zacks)
Feb-24-26 06:00PM	Nektar Therapeutics to Participate in Two Investor Conferences in March (PR Newswire) -7.06%
Feb-23-26 12:07PM	GeneDx Q4 Earnings Call Highlights (MarketBeat)
Feb-17-26 07:00AM	Nektar Therapeutics Announces Research Collaboration with UCSF and Dr. Stephen Hauser for NKTR-0165, a Tumor Necrosis Factor Receptor 2 (TNFR2) Antibody, in Multiple Sclerosis (PR Newswire)
Feb-13-26 04:15PM	Nektar Therapeutics Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)
Feb-11-26 10:23PM	Nektar Therapeutics Announces Pricing of Upsized $400 Million Public Offering (PR Newswire) +18.48% +7.01%
08:08AM	Nektar (NKTR) Soars 51.1%: Is Further Upside Left in the Stock? (Zacks)
07:42AM	Nektars stock rises 51% on Phase II Rezpeg AD maintenance win (Clinical Trials Arena)
07:35AM	Why Is Nektar Therapeutics Stock Gaining Wednesday? (Benzinga)
02:07AM	Nektar Therapeutics Touts 52-Week ResPEG Data in Atopic Dermatitis, Eyes Phase 3 Launch in Q2 (MarketBeat)
Feb-10-26 04:07PM	Has Dupixent Met Its Match? Rivals Nektar, Evommune Catapult On Eczema Results. (Investor's Business Daily) +51.07%
04:05PM	Nektar Therapeutics Announces Proposed Public Offering (PR Newswire)
11:57AM	Nektar Therapeutics Stock Is Trending Tuesday: What's Going On? (Benzinga)
07:13AM	Nektar, continuing comeback, says eczema drugs effects hold up in follow-up study (BioPharma Dive)
07:00AM	New REZOLVE-AD Maintenance Data in Atopic Dermatitis Demonstrate Rezpegaldesleukin Resulted in Durable and New Responses Across Key Disease Measurements with Both Monthly and Quarterly Dosing (PR Newswire)
Feb-09-26 04:15PM	Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Maintenance Period for its REZOLVE-AD Phase 2b Study of Rezpegaldesleukin in Atopic Dermatitis on February 10, 2026 (PR Newswire)
Feb-02-26 10:02PM	Nektar Therapeutics (NKTR): A Bull Case Theory (Insider Monkey)
Jan-30-26 04:10PM	Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +5.96%
Jan-08-26 09:36AM	Zacks Industry Outlook Highlights Soleno Therapeutics, Nektar Therapeutics, Rigel Pharmaceuticals, Ironwood Pharmaceuticals and Marker Therapeutics (Zacks)
Jan-07-26 08:45AM	5 Small Drug Stocks to Buy as Industry Recovery Picks Up (Zacks)
Jan-05-26 05:05PM	Ignore Nektar Therapeutics Stock in 2026 and Load Up on This One Instead (Motley Fool)
Dec-26-25 02:33AM	The Zacks Analyst Blog Mineralys, Lyell, Insmed and Nektar (Zacks)
Dec-24-25 10:51AM	4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow (Zacks)
Dec-21-25 07:31AM	Strong REZOLVE-AA Study Results Drive Analyst Confidence in Nektar Therapeutics (NKTR) (Insider Monkey)
Dec-16-25 07:30AM	REZOLVE-AA Phase 2b Study of Rezpegaldesleukin Establishes Proof-of-Concept in Patients with Severe-to-Very-Severe Alopecia Areata (PR Newswire) -7.77%
06:24AM	Nektar sees silver lining as autoimmune drug narrowly misses in alopecia study (BioPharma Dive)
Dec-15-25 06:00PM	Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025 (PR Newswire)
Dec-08-25 12:00PM	Here's Why Nektar Therapeutics (NKTR) is a Great Momentum Stock to Buy (Zacks)
Dec-05-25 06:00PM	Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Dec-01-25 09:55AM	Wall Street Analysts Believe Nektar (NKTR) Could Rally 64.53%: Here's is How to Trade (Zacks) -6.29%
Nov-26-25 09:43AM	Autodesk upgraded, Nio downgraded: Wall Street's top analyst calls (The Fly) +8.85%
Nov-23-25 07:02AM	Is Nektar Therapeutics (NKTR) The Hottest SMID-Cap Stock to Buy Now? (Insider Monkey)
Nov-20-25 06:57AM	Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know. (Motley Fool) -8.68%
Nov-13-25 09:55AM	Does Nektar (NKTR) Have the Potential to Rally 62.75% as Wall Street Analysts Expect? (Zacks) -6.45%
Nov-08-25 05:45PM	New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting (PR Newswire)
Nov-07-25 10:11AM	Nektar Therapeutics Q3 Loss Narrower Than Expected, Revenues Rise Y/Y (Zacks)
12:07AM	Nektar Therapeutics (NKTR) Q3 2025 Earnings Call Highlights: Strong Cash Position and Promising ... (GuruFocus.com)
Nov-06-25 05:55PM	Nektar Therapeutics (NKTR) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
05:06PM	Nektar: Q3 Earnings Snapshot (Associated Press Finance)
04:15PM	Nektar Therapeutics Reports Third Quarter 2025 Financial Results (PR Newswire)
Nov-03-25 10:00AM	Guardian Pharmacy Services (GRDN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks) -7.72%
Oct-30-25 06:00PM	Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London (PR Newswire) +5.32%
10:00AM	Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-28-25 06:00PM	Nektar to Announce Financial Results for the Third Quarter on Thursday, November 6, 2025, After Close of U.S.-Based Financial Markets (PR Newswire)
09:55AM	Wall Street Analysts See a 50.01% Upside in Nektar (NKTR): Can the Stock Really Move This High? (Zacks)
Oct-26-25 06:06AM	Nektar Therapeutics Data from REZOLVE-AD Study Accepted for Late-Breaking Oral Presentation (Insider Monkey)
Oct-22-25 08:00AM	Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting (PR Newswire)
Oct-13-25 08:37AM	This Stock Is Up By 285% This Year But Could Still Jump By 53%, According to Wall Street (Motley Fool) +5.63%
Oct-05-25 08:41AM	Here's Why Nektar Therapeutics Stock Rocketed 90.6% Higher in September (Motley Fool)
Sep-25-25 05:22AM	Zevra Therapeutics (ZVRA) Soars 10.4%: Is Further Upside Left in the Stock? (Zacks) -7.81%
Sep-21-25 06:43PM	These 2 Healthcare Stocks Are Up Over 100% in a Month. Can They Keep Climbing? (Motley Fool)
Sep-18-25 05:34PM	Why Nektar Therapeutics Stock Zoomed More Than 15% Higher Today (Motley Fool) +15.06% -6.16%
12:23PM	EADV 25: Nektar presents data from AD candidate that sent stocks flying (Clinical Trials Arena)
08:45AM	Nektar Presents New Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin in Late-Breaker Oral Presentation at EADV 2025 (PR Newswire)
Sep-09-25 07:00AM	Nektar Announces REZOLVE-AD Phase 2b Results for Rezpegaldesleukin Selected for Late-Breaker Oral Presentation at EADV 2025 (PR Newswire) +9.56%
Sep-08-25 11:27AM	NKTR Shares Surge 38.2% in a Week: Here's What You Should Know (Zacks) +10.33%
Sep-05-25 01:32PM	Why Nektar Therapeutics Rippled Higher This Week (Motley Fool) +11.67%
Sep-03-25 07:00PM	Nektar Therapeutics to Participate in Two Investor Conferences in September (PR Newswire) +26.02%
Aug-14-25 12:22PM	Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment (PR Newswire)
Aug-08-25 06:15PM	Why Nektar Therapeutics Stock Popped 6% on Friday (Motley Fool) +6.02%
11:45AM	Nektar Q2 Loss Narrower Than Expected, Revenues Fall Y/Y (Zacks)
Aug-07-25 05:30PM	Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:33PM	Nektar: Q2 Earnings Snapshot (Associated Press Finance)
04:15PM	Nektar Therapeutics Reports Second Quarter 2025 Financial Results (PR Newswire)
Aug-05-25 06:10PM	Rigel Pharmaceuticals (RIGL) Q2 Earnings and Revenues Surpass Estimates (Zacks)
Aug-04-25 11:55AM	Nektar Gears Up to Report Q2 Earnings: What's in the Cards? (Zacks)
10:00AM	Journey Medical Corporation (DERM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-31-25 06:00PM	Nektar to Announce Financial Results for the Second Quarter on Thursday, August 7, 2025, After Close of U.S.-Based Financial Markets (PR Newswire) +5.90%

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

CEOMr. Howard W. Robin

Senior VP and Chief Research & Development OfficerDr. Jonathan Zalevsky Ph.D.

CFO and Principal Financial & Accounting OfficerMs. Linda M. Rubinstein M.A.

Chief Accounting OfficerMr. Jason Barnard

VP of LegalMs. Elizabeth Zhang

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
JONATHAN ZALEVSKY	Officer	Jun 30 '26	Proposed Sale	65.39	5,681	371,481		Jun 30 04:36 PM
ROBIN HOWARD W	President & CEO	Jun 17 '26	Sale	61.19	10,000	611,880	55,045	Jun 18 07:08 PM
ROBIN HOWARD W	President & CEO	Jun 16 '26	Sale	60.32	10,000	603,176	65,045	Jun 18 07:08 PM
Zalevsky Jonathan	Chief R&D Officer	Jun 15 '26	Sale	60.71	5,538	336,212	15,437	Jun 17 07:12 PM
ROBIN HOWARD W	Officer	Jun 17 '26	Proposed Sale	60.27	10,000	602,700		Jun 17 11:05 AM
ROBIN HOWARD W	Officer	Jun 16 '26	Proposed Sale	60.96	10,000	609,600		Jun 16 11:07 AM
JONATHAN ZALEVSKY	Officer	Jun 15 '26	Proposed Sale	59.38	5,538	328,846		Jun 15 04:56 PM
Zalevsky Jonathan	Chief R&D Officer	May 19 '26	Sale	65.51	199	13,036	20,975	May 21 06:26 PM
ROBIN HOWARD W	President & CEO	May 19 '26	Sale	65.51	444	29,086	75,045	May 21 06:26 PM
Zalevsky Jonathan	Officer	May 19 '26	Proposed Sale	65.51	199	13,036		May 19 03:27 PM
ROBIN HOWARD W	Officer	May 19 '26	Proposed Sale	65.51	444	29,085		May 19 03:24 PM
Wilson Mark Andrew	Former Officer	Mar 13 '26	Proposed Sale	72.64	78,510	5,702,966		Mar 13 01:04 PM
Zalevsky Jonathan	Chief R&D Officer	Feb 18 '26	Sale	73.00	180	13,140	21,174	Feb 20 07:10 PM
ROBIN HOWARD W	President & CEO	Feb 18 '26	Sale	73.00	423	30,879	75,489	Feb 20 07:10 PM
ROBIN HOWARD W	Officer	Feb 18 '26	Proposed Sale	73.00	423	30,878		Feb 18 03:47 PM
Zalevsky Jonathan	Officer	Feb 18 '26	Proposed Sale	73.00	180	13,140		Feb 18 03:15 PM
Zalevsky Jonathan	Chief R&D Officer	Jan 20 '26	Sale	35.67	3,867	137,936	21,354	Jan 22 07:31 PM
Zalevsky Jonathan	Officer	Jan 20 '26	Proposed Sale	35.67	3,867	137,946		Jan 20 04:21 PM
Zalevsky Jonathan	Chief R&D Officer	Nov 25 '25	Sale	54.28	1,157	62,802	18,971	Nov 25 08:30 PM
Wilson Mark Andrew	Chief Legal Officer	Nov 25 '25	Sale	54.28	630	34,196	21,585	Nov 25 08:29 PM
ROBIN HOWARD W	President & CEO	Nov 25 '25	Sale	54.28	2,207	119,796	54,245	Nov 25 08:28 PM
ROBIN HOWARD W	Officer	Nov 25 '25	Proposed Sale	58.82	2,207	129,812		Nov 25 03:35 PM
Wilson Mark Andrew	Officer	Nov 25 '25	Proposed Sale	58.82	630	37,056		Nov 25 03:32 PM
Zalevsky Jonathan	Officer	Nov 25 '25	Proposed Sale	58.82	1,157	68,053		Nov 25 03:28 PM
ROBIN HOWARD W	President & CEO	Sep 09 '25	Sale	46.69	6,666	311,214	49,342	Sep 11 09:01 PM
ROBIN HOWARD W	Officer	Sep 09 '25	Proposed Sale	46.69	6,666	311,205		Sep 09 04:57 PM
Zalevsky Jonathan	Chief R&D Officer	Sep 04 '25	Sale	33.52	1,721	57,693	17,462	Sep 08 08:32 PM
ROBIN HOWARD W	President & CEO	Sep 05 '25	Sale	38.53	6,666	256,851	56,008	Sep 08 08:31 PM
ROBIN HOWARD W	President & CEO	Sep 04 '25	Sale	33.70	5,166	174,108	62,674	Sep 08 08:31 PM
ROBIN HOWARD W	Officer	Sep 05 '25	Proposed Sale	38.53	6,666	256,838		Sep 05 04:37 PM
Zalevsky Jonathan	Chief R&D Officer	Sep 02 '25	Sale	30.10	485	14,598	19,183	Sep 04 09:02 PM
ROBIN HOWARD W	President & CEO	Sep 02 '25	Sale	30.16	1,500	45,240	67,840	Sep 04 09:01 PM
ROBIN HOWARD W	Officer	Sep 04 '25	Proposed Sale	33.70	5,166	174,119		Sep 04 05:06 PM
Zalevsky Jonathan	Officer	Sep 04 '25	Proposed Sale	33.52	1,721	57,688		Sep 04 04:19 PM
Zalevsky Jonathan	Officer	Sep 02 '25	Proposed Sale	30.10	485	14,600		Sep 02 04:45 PM
ROBIN HOWARD W	Officer	Sep 02 '25	Proposed Sale	30.16	1,500	45,244		Sep 02 04:42 PM
Zalevsky Jonathan	Chief R&D Officer	Aug 19 '25	Sale	26.59	725	19,278	19,668	Aug 21 09:05 PM
Wilson Mark Andrew	Chief Legal Officer	Aug 19 '25	Sale	26.59	676	17,975	20,312	Aug 21 09:04 PM
ROBIN HOWARD W	President & CEO	Aug 19 '25	Sale	26.59	1,573	41,826	69,340	Aug 21 09:03 PM
ROBIN HOWARD W	Officer	Aug 19 '25	Proposed Sale	26.59	1,573	41,826		Aug 19 03:24 PM
Wilson Mark Andrew	Officer	Aug 19 '25	Proposed Sale	26.59	676	17,975		Aug 19 03:24 PM
Zalevsky Jonathan	Officer	Aug 19 '25	Proposed Sale	26.59	725	19,278		Aug 19 03:20 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

$100 Off Your First Year Get Elite For Just $199.50

NKTR

Nektar Therapeutics

Upgrade your Finviz experience